US News

Regeneron COVID-19 therapy cuts deaths among hospitalised patients who lack antibodies -study

Published by
Reuters

By Alistair Smout LONDON (Reuters) – Regeneron Pharmaceuticals Inc’s COVID-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday found. The therapy, REGEN-COV, has been granted emergency use authorisation for people with mild-to-moderate COVID-19 in the United States, but results from the RECOVERY trial provide the clearest evidence of its effectiveness among hospitalised patients. It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with CO…

Read More

Facebook Comments

Check Also

Challengers in German election jointly demand 12-euro minimum wage

Published by DPA The two candidates trying to ...

Archives